Line 2,271: |
Line 2,271: |
| |- | | |- |
| |ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | | |ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || |
− | | | + | |Anaplastic Large Cell Lymphoma, ALK-Positive |
− | | | + | |Miguel Gonzalez Mancera, MD |
− | | | + | |
− | | | + | Sumire Kitahara, MD |
| + | |
| + | Cedars-Sinai, Los Angeles, CA |
| + | |Complete |
| + | |09/23/2022 |
| | | | | |
| |- | | |- |
| |ALK-negative anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | | |ALK-negative anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || |
− | | | + | |Anaplastic Large Cell Lymphoma, ALK-Negative |
| |Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA | | |Miguel Gonzalez Mancera, MD Sumire Kitahara, MD Cedars-Sinai, Los Angeles, CA |
− | | | + | |Complete |
− | | | + | |09/23/2022 |
| | | | | |
| |- | | |- |
| |Breast implant-associated anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || | | |Breast implant-associated anaplastic large cell lymphoma||Disease|| || || || || ||SK|| || |
− | | | + | |Breast Implant-Associated Anaplastic Large Cell Lymphoma |
| |Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center | | |Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD Cedars-Sinai Medical Center |
− | | | + | |Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease|| || || || || ||SK|| || | + | |Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease||Issue - Rachel Burnside was working on this. Note says: "has prior content and name will change in 5th edition - Rachel working on this outside of production site to be replaced later by Nodal TFH Cell Lymphoma, Angioimmunoblastic-Type)". Where is her content as previous author names on 5th edition page||7/28/2023 |
− | | | + | | ||Pending|| ||SK|| || |
− | |* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG | + | |Angioimmunoblastic T-cell Lymphoma |
− | | | + | |Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG |
| + | |Pending |
| | | | | |
| | | | | |
| |- | | |- |
− | |Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| || | + | |Nodal TFH cell lymphoma, follicular-type||Disease||Rachel Burnside||7/28/2023 |
− | | | + | | ||Pending|| ||SK|| || |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
− | | | + | |NEW (No Prior) |
| + | |NEW (No Prior) |
| |- | | |- |
| |Nodal TFH cell lymphoma, NOS||Disease|| || || || || ||SK|| || | | |Nodal TFH cell lymphoma, NOS||Disease|| || || || || ||SK|| || |